scPharmaceuticals, Inc. (SCPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1160364,
    "name": "scPharmaceuticals, Inc.",
    "stock_name": "scPharmaceuticals, Inc.",
    "full_name": "scPharmaceuticals, Inc.",
    "name_url": "stocks-analysis/scpharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.67",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "5.67",
    "mcapval": "297.40",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US8106481059",
    "curr_date": "Oct 08",
    "curr_time": "",
    "bse_nse_vol": "0 ",
    "exc_status": "Active",
    "traded_date": "Oct 08, 2025",
    "traded_date_str": "2025 10 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/scpharmaceuticals-inc-1160364-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is scPharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-scpharmaceuticals-inc-technically-bullish-or-bearish-3547456",
        "imagepath": "",
        "date": "2025-09-20 19:55:41",
        "description": "As of 22 August 2025, the technical trend for scPharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe, while the KST is bullish weekly and mildly bullish monthly. However, the Dow Theory presents a mildly bullish weekly and bearish monthly outlook, which adds some caution.\n\nIn terms of performance, scPharmaceuticals has outperformed the S&P 500 over the past month with a return of 17.57% compared to the S&P 500's 2.33%, but it has lagged over longer periods, particularly in the 5-year and 10-year comparisons. Overall, the current technical stance is bullish, supported by several key indicators, although the mixed signals from Dow Theory suggest a need for vigilance...."
      },
      {
        "title": "Is scPharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-scpharmaceuticals-inc-overvalued-or-undervalued-3543815",
        "imagepath": "",
        "date": "2025-09-20 18:29:26",
        "description": "As of 10 May 2023, the valuation grade for scPharmaceuticals, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -43.25, an EV to EBIT of -3.23, and an EV to EBITDA of -3.24. Compared to peers, scPharmaceuticals has a worse EV to EBITDA ratio than Lexicon Pharmaceuticals, Inc. at -2.8670 and Fulcrum Therapeutics, Inc. at -2.2319, both of which also carry a risky valuation grade.\n\nIn terms of stock performance, scPharmaceuticals has shown a year-to-date return of 58.76%, significantly outperforming the S&P 500's 12.22% during the same period, though it lags behind in longer-term comparisons. Overall, the combination of negative valuation metrics and the risky classification suggests that scPharmaceuticals is overvalued in the current market context...."
      }
    ],
    "total": 7,
    "sid": "1160364",
    "stock_news_url": "https://www.marketsmojo.com/news/scpharmaceuticals-inc-1160364"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is scPharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:55:41

As of 22 August 2025, the technical trend for scPharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe, while the KST is bullish weekly and mildly bullish monthly. However, the Dow Theory presents a mildly bullish weekly and bearish monthly outlook, which adds some caution. In terms of performance, scPharmaceuticals has outperformed the S&P 500 over the past month with a return of 17.57% compared to the S&P 500's 2.33%, but it has lagged over longer periods, particularly in the 5-year and 10-year comparisons. Overall, the current technical stance is bullish, supported by several key indicators, although the mixed signals from Dow Theory suggest a need for vigilance....

Is scPharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:29:26

As of 10 May 2023, the valuation grade for scPharmaceuticals, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -43.25, an EV to EBIT of -3.23, and an EV to EBITDA of -3.24. Compared to peers, scPharmaceuticals has a worse EV to EBITDA ratio than Lexicon Pharmaceuticals, Inc. at -2.8670 and Fulcrum Therapeutics, Inc. at -2.2319, both of which also carry a risky valuation grade. In terms of stock performance, scPharmaceuticals has shown a year-to-date return of 58.76%, significantly outperforming the S&P 500's 12.22% during the same period, though it lags behind in longer-term comparisons. Overall, the combination of negative valuation metrics and the risky classification suggests that scPharmaceuticals is overvalued in the current market context....

View All News